×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 9 Track 2: Extra/Non-Hepatic Delivery
Session Chair(s)
Jeffrey Foy, PhD
Senior VP, Toxicology
PepGen Inc., United States
Sree Rayavarapu, DVM, PhD
Toxicologist
FDA, United States
This session will describe strategies for targeting extra-hepatic organs and will feature data from sponsor programs. Delivery technologies, nonclinical study design considerations, and pharmacology, ADME, and toxicology data will be discussed.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize current efforts to deliver oligonucleotide-based products to cells or organs outside of the liver
- Have a greater understanding of the challenges associated with delivering oligos to muscle, lung, and brain
Speaker(s)
Development of a Novel Muscle-targeted Antibody Oligonucleotide Conjugate for the Treatment of Myotonic Dystrophy Type 1: Toxicology and Regulatory Approaches and Considerations
Eileen Blasi, MS, MSc
Avidity Biosciences, United States
Senior Director of Toxicology
Nonclinical Development of Inhaled Oligonucleotides: Nothing Good Comes Easily
Jessica Grieves, DVM, PhD
Ionis Pharmaceuticals, United States
Director, Pathology and Nonclinical Development
Speaker
Vignesh Narayan Hariharan, PhD
University of Massachutes Medical School, United States
Instructor
Have an account?